Syndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge
Syndax Pharmaceuticals (SNDX) reported that its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed the primary endpoint. The trial evaluated the drug's efficacy and safety in 145 patients across 62 sites. Despite the setback, axatilimab was well tolerated, and Syndax will continue its development for chronic graft-versus-host disease (cGVHD).
How this was made
The 30-second read
Why it matters
The failed IPF trial removes a potential new indication, likely reducing near-term growth expectations and prompting a sell-off.
Market read
First disclosure of a negative Phase 2 trial for a listed biotech, causing immediate price decline.
What to watch
Strong cash position ($575M) and growing revenue from Niktimvo could support the stock despite the setback.
Background
Syndax (NASDAQ:SNDX) is a biotech focused on oncology and rare diseases. Axatilimab is approved for chronic graft-versus-host disease.
Ticker impact
Syndax announced its Phase 2 MAXPIRe trial of axatilimab in IPF missed the primary endpoint, prompting a 16% drop in the stock.
downward pressure as the market prices in the missed endpoint and halted IPF development
The article is the first report of the negative trial result, shares already fell 16% overnight, and the company will not pursue further IPF development.
Market effects
May weigh on other biotech firms with late-stage IPF programs as investors reassess risk.
Limited to US-listed biotech sector.
Minimal beyond the biotech niche.
Counterpoint
If the company can redirect axatilimab to cGVHD pipelines, the long-term outlook may remain intact.
Key entities
- ExecutiveMichael A. Metzger
CEO of Syndax, quoted on continued focus on revumenib and axatilimab.
